Sökresultat

What is the best approach for treating Alzheimer's disease? Aducanumab is an amyloid beta-directed monoclonal antibody that targets the aggregated forms of amyloid beta found in the brains of people with Alzheimer's disease. In May, Dr. Niklas Mattsson-Carlgren and Dr. Ruben Smith entertained young MultiParkers by debating the pros and cons of using it. Last summer, Aducanumab was approved by the

https://www.multipark.lu.se/article/multipark-debate-aducanumab-yesno - 2025-12-07

The Royal Swedish Academy of Sciences has elected two new members of the Academy’s class for medical sciences. One of them is Malin Parmar, Professor of Cellular Neuroscience at Lund University. Together with her research group, Malin Parmar has conducted several groundbreaking studies on stem cells that have led to the development of new treatments for patients with Parkinson’s disease. Using kno

https://www.multipark.lu.se/article/malin-parmar-elected-royal-swedish-academy-sciences - 2025-12-07

Inflammatory responses in the brain have long been suspected of playing a role in Alzheimer’s disease, but are challenging to monitor in the living human brain. An international collaboration including researchers at MultiPark, Lund University has made it possible to detect elevated levels of Galectin-3, a protein expressed in the immune cells inside the brain. The results were published in Acta N

https://www.multipark.lu.se/article/biomarker-reveals-inflammatory-changes-brain-alzheimers-disease - 2025-12-07

Cell replacement therapy has long been a hope for patients with Parkinson’s disease and efforts are on their way to use stem cell derived-dopaminergic neurons in clinical trials. On 14 October, Jessica Giacomoni defends her thesis. Her project about the direct conversion of human glial cells into therapeutic neurons directly within the brain has the ultimate goal to become an alternative to cell t

https://www.multipark.lu.se/article/turning-glia-neurons-inside-brain-phd-interview-jessica-giacomoni - 2025-12-07

Numerous studies have suggested that eating a healthy diet may reduce a person’s risk of dementia. A new study from one of MultiPark's research groups, published in Neurology, sheds new light on the impact of having a Mediterranean diet. The Mediterranean diet includes a high intake of vegetables, legumes, fruits, fish and healthy fats such as olive oil, and a low intake of dairy products, meats a

https://www.multipark.lu.se/article/does-mediterranean-diet-really-decrease-your-risk-dementia - 2025-12-07

An investigational stem cell-based therapy for the treatment of Parkinson’s Disease, STEM-PD, has been given regulatory approval for a Phase I/IIa clinical trial. Ethical approval of the trial has already been obtained from the Swedish Ethics Review Authority, and the STEM-PD team, led from Lund University in Sweden, is thereby ready to proceed with the trial. “We are excited and looking forward t

https://www.multipark.lu.se/article/swedish-medical-products-agency-grants-approval-clinical-study-new-stem-cell-based-parkinsons - 2025-12-07

Matilde Negrini’s thesis project has been to develop and characterize a rat model of Parkinson’s disease. November 4, she defends her thesis. Here, she talks about her project and most proud moments during her Ph.D. journey. Tell us about your research! My project has been to develop and characterize a rat model of Parkinson’s disease based on the Parkinson’s-related protein alpha-synuclein. This

https://www.multipark.lu.se/article/modelling-parkinsons-disease-phd-interview-matilde-negrini - 2025-12-07

MultiPark’s scientists conduct world-leading research in biomarkers for Alzheimer’s disease, led by Professor Oskar Hansson at the memory clinic at Skåne University Hospital. He recently met with Bill Gates to discuss the future possibilities in this field. You met with Bill Gates yesterday in Brussels. Why did he want to meet you there? Already five years ago, Gill Gates understood the importance

https://www.multipark.lu.se/article/multipark-researcher-bill-gates-brussels - 2025-12-07

A large study led by Lund University in Sweden has shown that people with Alzheimer's disease can now be identified before they experience any symptoms. It is now also possible to predict who will deteriorate within the next few years. The study is published in Nature Medicine, and is very timely in light of the recent development of new drugs for Alzheimer's disease. It has long been known that t

https://www.multipark.lu.se/article/alzheimers-disease-can-be-diagnosed-symptoms-emerge - 2025-12-07

MultiPark’s backbone for research interactions is about to be reorganized. The 13 new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development and network formation to our young scientists. The SIGs are self-organizing and self-managing groups. Brian Circuit Analysis is one of them with already ongoing activities. An

https://www.multipark.lu.se/article/brain-circuit-analysis-special-interest-group - 2025-12-07

The glymphatic system clears waste products from the brain. Roberta Battistella defends her thesis about the role of this system in Parkinson’s disease on December 1. Here, she tells about her time as a Ph.D student in Iben Lundgaards research group at MultiPark. Tell us about your research! “The glymphatic system removes waste products from the brain with the help of cerebrospinal fluid (CSF). It

https://www.multipark.lu.se/article/glymphatic-system-pd-phd-interview-roberta-battistella - 2025-12-07

The brain's big-eating immune cells can slow down the progression of Alzheimer's disease. This is shown by a study that is now published in Nature Aging. The brain's own immune cells are called microglia and are found in the central nervous system. They are big eaters that kill viruses, damaged cells and infectious agents they come across. It has long been known that microglial cells can be activa

https://www.multipark.lu.se/article/brains-immune-cells-can-be-triggered-slow-down-alzheimers-disease - 2025-12-07

Walking is probably more cognitively demanding than you think. Magnus Lindh-Rengifo defends his thesis about walking aspects in neurodegenerative disorders on December 16. Read about his experiences as a Ph.D student at MultiPark. Tell us about your research! “Walking capability can be a key feature to being able to participate in meaningful activities in your daily life. Meeting patients with neu

https://www.multipark.lu.se/article/walking-neurodegeneration-phd-interview-magnus-lindh-rengifo - 2025-12-07

A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also another blood test that is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression. The article was originally published as a press release from the Sahlgrenska Academy, Univer

https://www.multipark.lu.se/article/optimal-blood-tests-development-new-therapies-alzheimers-disease - 2025-12-07

“Lundensare” Nobel Prize winner Arvid Carlsson (1923-2018) did not receive the prestigious Nobel Prize while living or working in Lund – but he is an alumnus! Carlsson grew up in Lund (which could clearly be heard in his Lund accent) and in 1951 he became a doctor of medicine at Lund University. He was employed as an associate professor of pharmacology and in 1959 he left for Gothenburg, where he

https://www.multipark.lu.se/article/nobel-prize-winner-arvid-carlsson-7-things-you-perhaps-did-not-know-about-him-and-his-research - 2025-12-07

MultiPark’s new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development and network formation to our young scientists. One of them focus on molecular signaling. Lautaro Belfiori is the convening person. He shares with us how they plan to work with questions related to molecular signaling. Can you shortly describe th

https://www.multipark.lu.se/article/molecular-signaling-neurodegenerative-disorders-special-interest-group - 2025-12-07

Keivan Javanshiri’s Ph.D. project explores cardiac and vascular pathologies in Lewy body dementia and Alzheimer's disease. January 20, he defends his thesis. Here, he shares the most important findings and why sudden cardiac arrest is a common cause of death in patients with Lewy body disease. Tell us about your research! “My research focuses on cognitive disorders, which you may envision like a t

https://www.multipark.lu.se/article/cognitive-disease-beyond-brain-phd-interview-keivan-javanshiri - 2025-12-07

We ended the MultiPark year in December as we started it in January: with a MultiPark Retreat! The December retreat was our first big meeting IRL after the pandemic, and it turned out to be a much appreciated event. Thank you to all participants, and thank you once again to the retreat organizing committee for doing such a great job! 2022 was a year of “reopening”. Like a butterfly spreads its win

https://www.multipark.lu.se/article/multipark-closing-circle-2022-and-looking-forward-2023 - 2025-12-07

Katrine Skovgård’s Ph.D. project sheds light on the dysfunctions in the brain through which dopaminergic pharmacotherapies for Parkinson’s disease affect motor behaviors. January 19, she defends her thesis. She explains how better experimental models might improve future translational research on dyskinesia. You presented your research at the MultiPark Café recently. But for those who could not at

https://www.multipark.lu.se/article/why-dopamine-receptor-type-matters-phd-interview-katrine-skovgard - 2025-12-07

At the end of October 2022, the Swedish Medical Products Agency gave the go-ahead for a clinical trial of the stem cell-based therapy STEM-PD for the treatment of Parkinson’s disease. The cells, generated from embryonic stem cells, have been in development for several years and will now be transplanted into patients with Parkinson’s to replace nerve cells lost due to the disease. The clinical tria

https://www.multipark.lu.se/article/nerve-cells-could-transform-treatment-parkinsons - 2025-12-07